Specialty Pharmacy

Top news of the day from across the health care landscape.

Cancer treatment also reduced the rates of severe bone complications by more than half.

Gel is 3 times more effective among women with Lactobacillus-dominate microbiome.

Acne medication can slow the progression of relapsing-remitting MS in patients who experienced their first symptoms.

Unique one-day conference precedes National Association of Specialty Pharmacy’s 5th Annual Meeting and Educational Conference.

Pertuzumab-based regimen found to reduce the risk of invasive breast cancer recurrence by 19%.

Additional support programs found to benefit the physical and emotional needs of patients with RA.

Research team will seek to develop a novel prophylactic vaccine to prevent HCV.

HIV-positive women had higher rates of acquiring HPV and lower rates of clearing HIV infection.

Eli Lilly will present 27 abstracts on the safety and long-term efficacy for rheumatoid arthritis and psoriasis drugs.

Top news of the day from across the health care landscape.

Recent pharmacy school graduates will find the benefits of investing in professional development to open new career paths.

Analogs of epothilones were even effective against a drug-resistant cancer cell line.

Psoriasis drugs Cosentyx and Taltz demonstrated significantly more remissions in patients with psoriasis.

Genomic approach increases understanding of cancer.

LED light could be used to direct immune cells to superficial tumors.

AstraZeneca and GlaxoSmithKline are key players in the COPD market.

Top news of the day from across the health care landscape.

Compound in olive oil inhibits disease activity of certain proteins.

The software helps track Interferon beta-1b injections among MS patients.

Sequence of drug administration is crucial to the success of combination treatments for cancer using cannabinoids.

Medications that suppress viral loads aid HIV-infected men who want children.

The drug offers a new therapeutic option to help manage RA.

HCV drug greatly reduced the rates of liver transplants and mortality in patients with advanced stages of cirrhosis.

The guide seeks to provide health care professionals with reference information on the science and regulation underpinning biosimilar use.

Top news of the day from across the health care landscape.

The FDA recommends a 200-mg dose of pembrolizumab every 3 weeks, but researchers disagree.

Another state passes legislation to increase uptake of biosimilars.